Orthopediatrics Corp.

KIDS

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001425450

A

strongest fifth of 370 graded peers in healthcare

rank 42 of 370; percentile 11.1; sampling error 2.5 points; lower is stronger


A B C D E

A, the bull




Scoreboard	
Profitability	B percentile 35.7
Solvency	B percentile 28.8
Growth and financing	B percentile 36.3
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $508.6M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	9 of 14
Graded from	filings received through Mar 4, 2026 236 days before the rescan; latest periodic filing 10-Q received Aug 5, 2026
Last close	$24.50 2026-10-23; market equity $639.6M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 4, 2026

OrthoPediatrics Corp. (the "Company") is a Delaware corporation, headquartered in Warsaw, Indiana, and organized in November 2007. The Company's Common Stock is traded on the Nasdaq Global Market under the symbol KIDS. OrthoPediatrics Corp. is a medical device company committed to designing, developing and marketing anatomically appropriate implants, instruments and specialized braces for children with orthopedic conditions, giving pediatric orthopedic surgeons and caregivers the ability to treat children with technologies specifically designed to meet their needs. Initially organized as an Indiana limited liability company on August 31, 2006, OrthoPediatrics Corp.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 35.7						
Gross profitability	33.9%	32.3%		41.1	368	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Accruals ratio	(7.1%)	(6.6%)	53.1	807	2025-12-31
Gross margin stability, five years	0.9 pts	2.8 pts	12.9	242	2025-12-31
Solvency, sleeve percentile 28.8					
Twelve-month failure probability	0.04%	0.07%	26.7	248	2026-06-30
Altman Z double-prime	2.67	(0.33)	26.8	752	2025-12-31
Net debt to EBITDA	not computable	1.82x			
EBITDA must exceed $100,000					
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2020-12-31; latest annual assets end 2025-12-31					
Current ratio	5.55x	2.94x	32.8	834	2025-12-31
Growth and financing, sleeve percentile 36.3					
Revenue growth, three-year compound	24.6%	10.1%	26.9	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	5.9%	2.1%	39.2	700	2025-12-31
Net share issuance, one year	4.1%	2.5%	42.8	636	2026-02-28

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
37	Viridian Therapeutics, Inc.\DE (VRDN)	9.8	A	dilution, fortress balance sheet
38	LivaNova plc (LIVN)	10.0	A	fortress balance sheet
39	TG Therapeutics, Inc. (TGTX)	10.3	A	
40	TransMedics Group, Inc. (TMDX)	10.6	A	
41	Niagen Bioscience, Inc. (NAGE)	10.8	A	
42	Orthopediatrics Corp. (KIDS)	11.1	A	
43	BridgeBio Pharma, Inc. (BBIO)	11.4	A	
44	PRO DEX Inc. (PDEX)	11.7	A	
45	Sanara MedTech Inc. (SMTI)	11.9	A	
46	Idexx Laboratories Inc. (IDXX)	12.2	A	
47	Natera, Inc. (NTRA)	12.5	A	fortress balance sheet

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	25.8%	7.7%	62
Distance from 52-week high	(7.5%)	(31.4%)	80
EBIT to enterprise value	(5.4%)	(1.5%)	41
Free cash flow yield	(2.5%)	(1.0%)	47

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	0.54	0.28	72
Sales to price	0.37	0.30	56
Composite equity issuance, five years	28.4%	20.5%	56
Relative strength against the sector, log excess return	0.02	(0.14)	62

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 4 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	pass
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$17.0M
Operating cash flow, four quarters	$7.4M
Months of runway	not finite
Days since last periodic filing	82 (10-Q received Aug 5, 2026)
Median daily dollar volume, 63 sessions	$4.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$172.7M	2025-12-31	2026-03-04	10-K	26-000013
2	assets	us-gaap:Assets	$508.6M	2025-12-31	2026-03-04	10-K	26-000013
3	operating income	us-gaap:OperatingIncomeLoss	-$39.2M	2025-12-31	2026-03-04	10-K	26-000013
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$39.2M	2025-12-31	2026-03-04	10-K	26-000013
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$460,000	2025-12-31	2026-03-04	10-K	26-000013
6	total debt	us-gaap:LongTermDebt	$106.0M	2025-12-31	2026-03-04	10-K	26-000013
7	book equity	us-gaap:StockholdersEquity	$346.6M	2025-12-31	2026-03-04	10-K	26-000013
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$19.6M	2025-12-31	2026-03-04	10-K	26-000013
9	total debt	us-gaap:LongTermDebt	$77.5M	2024-12-31	2026-03-04	10-K	26-000013
10	book equity	us-gaap:StockholdersEquity	$354.6M	2024-12-31	2026-03-04	10-K	26-000013
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$43.8M	2024-12-31	2026-03-04	10-K	26-000013
12	net income	us-gaap:NetIncomeLoss	-$39.6M	2025-12-31	2026-03-04	10-K	26-000013
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$4.9M	2025-12-31	2026-03-04	10-K	26-000013
14	assets	us-gaap:Assets	$473.2M	2024-12-31	2026-03-04	10-K	26-000013
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$236.3M	2025-12-31	2026-03-04	10-K	26-000013
16	gross profit	us-gaap:GrossProfit	$148.6M	2024-12-31	2026-03-04	10-K	26-000013
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$204.7M	2024-12-31	2026-03-04	10-K	26-000013
18	gross profit	us-gaap:GrossProfit	$111.3M	2023-12-31	2026-03-04	10-K	26-000013
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$148.7M	2023-12-31	2026-03-04	10-K	26-000013
20	gross profit	us-gaap:GrossProfit	$90.7M	2022-12-31	2025-03-05	10-K	25-000015
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$122.3M	2022-12-31	2025-03-05	10-K	25-000015
22	gross profit	us-gaap:GrossProfit	$73.4M	2021-12-31	2024-03-08	10-K	24-000013
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$98.0M	2021-12-31	2024-03-08	10-K	24-000013
24	current assets	us-gaap:AssetsCurrent	$256.4M	2025-12-31	2026-03-04	10-K	26-000013
25	current liabilities	us-gaap:LiabilitiesCurrent	$46.2M	2025-12-31	2026-03-04	10-K	26-000013
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$275.2M	2025-12-31	2026-03-04	10-K	26-000013

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	liabilities	us-gaap:Liabilities	$162.0M	2025-12-31	2026-03-04	10-K	26-000013
28	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$21.1M	2025-12-31	2026-03-04	10-K	26-000013
29	operating income	us-gaap:OperatingIncomeLoss	-$26.8M	2020-12-31	2023-03-01	10-K	23-000024
30	interest expense	us-gaap:InterestExpense	$3.4M	2020-12-31	2021-03-11	10-K	21-000047
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$11.1M	2025-12-31	2026-03-04	10-K	26-000013
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$27.0M	2024-12-31	2026-03-04	10-K	26-000013
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$14.3M	2024-12-31	2026-03-04	10-K	26-000013
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$27.0M	2023-12-31	2026-03-04	10-K	26-000013
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$16.9M	2023-12-31	2026-03-04	10-K	26-000013
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$21.8M	2022-12-31	2025-03-05	10-K	25-000015
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$10.0M	2022-12-31	2025-03-05	10-K	25-000015
38	current assets	us-gaap:AssetsCurrent	$237.2M	2024-12-31	2026-03-04	10-K	26-000013
39	current liabilities	us-gaap:LiabilitiesCurrent	$34.0M	2024-12-31	2026-03-04	10-K	26-000013
40	assets	us-gaap:Assets	$438.7M	2023-12-31	2025-03-05	10-K	25-000015
41	assets	us-gaap:Assets	$427.7M	2022-12-31	2024-03-08	10-K	24-000013
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	25,278,787	2026-02-28	2026-03-04	10-K	26-000013
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	24,286,590	2025-03-01	2025-03-05	10-K	25-000015

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.